Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov;32 Suppl 2(Suppl 2):S357-61.
doi: 10.2337/dc09-S339.

A summary of the ADVANCE Trial

Simon R Heller  1 ; ADVANCE Collaborative Group
Affiliations

A summary of the ADVANCE Trial

Simon R Heller et al. Diabetes Care. 2009 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Enrollment, randomization, and follow-up of study participants.
Figure 2
Figure 2
A1C at baseline and during follow-up, according to glucose-control strategy. Data are shown for mean glycated hemoglobin. The average difference between the intensive-control group and the standard-control group for the follow-up period was 0.67 percentage points (95% CI 0.64–0.70).
Figure 3
Figure 3
Cumulative incidences of events, according to glucose-control strategy. The hazard ratios for intensive glucose control compared with standard glucose control were as follows: for combined major macrovascular or microvascular events, 0.90 (95% CI 0.82–0.98) (A); for major macrovascular events, 0.94 (0.84–1.06) (B); for major microvascular events, 0.86 (0.77–0.97) (C); and for death from any cause, 0.93 (0.83–1.06) (D). The vertical dashed lines indicate the 24- and 48-month study visits, at which additional data on microvascular events were collected, specifically the ratio of urinary albumin to creatinine and results of a retinal examination. For events relating to these data, the event time was recorded as the date of the visit. The curves were truncated at month 66, by which time 99% of the events had occurred. The effects of treatment (hazard ratios and P values) were estimated from unadjusted Cox proportional-hazard models that used all the available data.
Figure 4
Figure 4
Relative effects of glucose-control strategy on microvascular disease. The diamonds incorporate the point estimates, represented by the vertical dashed lines, and the 95% CIs of the overall effects within categories; for subcategories, black squares represent point estimates (with the area of the square proportional to the number of events), and horizontal lines represent 95% CIs. The hazard ratios and relative risk reductions are given for intensive glucose control compared with standard glucose control.
See this image and copyright information in PMC

References

    1. U.K. Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837– 853 - PubMed
    1. Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 683– 689 - PubMed
    1. U.K. Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713– 720 - PMC - PubMed
    1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405– 412 - PMC - PubMed
    1. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560– 2572 - PubMed

MeSH terms